|
Tuesday, February 16, 2016
The February 2016 issue of the journal Complementary Therapies in Clinical Practice published the findings of a randomized, double-blind trial which revealed a reduction in markers of oxidative stress, inflammation and other factors in overweight and obese adults given a pomegranate extract supplement.
The trial included 48 participants assigned to receive 1000 milligrams pomegranate extract or a placebo daily for 30 days. Plasma malondialdehyde (MDA, a marker of lipid peroxidation), high-sensitivity C-reactive protein and interleukin-6 (inflammation markers), serum lipid and glucose levels, and insulin resistance were evaluated at the beginning and end of the trial.
At the end of the treatment period, average serum insulin, glucose, total and low-density lipoprotein cholesterol, plasma MDA, interleukin-6, C-reactive protein, and insulin resistance had significantly decreased from values ascertained before treatment among subjects who received pomegranate extract in comparison with changes that occurred in the placebo group. Additionally, high-density lipoprotein cholesterol increased among those who received pomegranate, while remaining at a similar level in subjects who received a placebo.
"Based on the findings from this study, it can be concluded that pomegranate extract consumption had a beneficial effect on oxidative stress, systemic inflammation and glycemic biomarkers, as well as lipid profiles," authors Banafshe Hosseini of Tehran University of Medical Sciences and colleagues conclude. "To our knowledge this is the first study addressing the effect of 30 days pomegranate extract consumption on markers of lipid peroxidation, inflammation and metabolic profiles among obese and overweight individuals."
"Our study suggests that pomegranate extract consumption may reduce complications linked with obesity," they conclude. |
|